Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study-Reference-Cited by-同舟云学术

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study

Published:2001-10 Issue:9288 Volume:358 Page:1119-1123
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Channick Richard N,Simonneau Gérald,Sitbon Olivier,Robbins Ivan M,Frost Adaani,Tapson Victor F,Badesch David B,Roux Sébastien,Rainisio Maurizio,Bodin Frédéric,Rubin Lewis J

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Primary pulmonary hypertension;Rubin;N Engl J Med,1997

2. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis;Stupi;Arthritis Rheum,1986

3. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension;Rich;N Engl J Med,1992

4. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension;Barst;Chest,1986

5. Survival in patients with primary pulmonary hypertension: results from a national prospective registry;D'Alonzo;Ann Intern Med,1991

Cited by 1322 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Prospect and Challenges of Repurposing Established Drugs in Pulmonary Arterial Hypertension;BioChem;2024-09-10

2. Treatment algorithm for pulmonary arterial hypertension;European Respiratory Journal;2024-08-29

3. Removing the FDA’s Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan;JAMA Network Open;2024-07-18

4. Calcium channel blockers in patients with pulmonary arterial hypertension receiving PAH-specific treatment;International Journal of Cardiology;2024-07

5. Using nano polymeric micelles based on beta cyclodextrin for the targeted delivery of bosentan drug;2024-04-11